Behavioral Health Glossary
Plain-language definitions for the clinical terms you will encounter on this site and in the treatment system. Engineered for a lay audience. Clinically accurate.
- The behavioral health treatment system runs on acronyms. IOP, PHP, ASAM, MOUD, CRAFT. Most of them are never explained to the people who need them most.
- Every term on this page is defined the way a good clinician would explain it to a patient: no secondary jargon, no hedging, no fluff.
- Hover over any underlined term elsewhere on this site to see its definition inline. This page is the full reference.
- Use the search box or jump links below to find a specific term fast.
No terms match your search.
The national clinical standard used by providers and insurance companies to calculate exactly what level of treatment a patient requires. The criteria evaluate six dimensions of a patient's life, including withdrawal risk, medical conditions, mental health, and social environment, then map the profile to a specific level of care. Insurance companies use ASAM to decide what they will pay for. Understanding these criteria is the foundation of self-advocacy in the treatment system.
Related: How ASAM 4th Edition works
The complete spectrum of treatment options available, ranging from weekly one-hour therapy sessions all the way up to 24-hour medical detox and residential care. The continuum is not a ladder that everyone climbs in order. A person can enter at any point, step up if the situation escalates, or step down as stability improves.
A mid-level treatment tier requiring 9 to 15 hours of attendance per week, typically structured as three or more days of group therapy, skills training, and case management. Designed to allow patients to keep their jobs, live at home, and maintain family responsibilities while receiving structured clinical care. ASAM Level 2.1. Most IOPs run in the morning or evening to accommodate work schedules.
Related: PHP vs. IOP: who fits where
The specific intensity of treatment a patient is placed into, matched to their clinical severity. The standard levels (defined by ASAM) run from Level 0.5 (early intervention) through Level 1 (standard outpatient), Level 2.1 (IOP), Level 2.5 (PHP), Level 3.1 to 3.7 (residential), and Level 4 (medically managed inpatient). The goal is to match level to need, not to default everyone to the most intensive option.
The least intensive formal level of care, usually consisting of 1 to 3 hours of individual or group therapy per week. ASAM Level 1. Appropriate for people with mild-to-moderate substance use disorders who have a stable living environment and a functioning support system. Often combined with medication management and mutual-help groups.
A highly structured day program requiring 20 or more hours of attendance per week, typically five days a week from morning to mid-afternoon. Patients return home or to a sober living environment each night. ASAM Level 2.5. Clinically, PHP sits between IOP and residential care and is often used as a step-down from residential rather than a first entry point.
Related: PHP vs. IOP: who fits where
A 24-hour live-in facility focused on behavioral health interventions, group therapy, and structured daily programming. Universally referred to by the public as "rehab." ASAM Levels 3.1 through 3.7, depending on medical staffing intensity. Indicated for patients with unstable living environments, severe withdrawal risk, or treatment needs that cannot be met in lower levels of care.
Related: What rehab actually means
The process where an insurance company evaluates a provider's clinical assessment to decide if they will authorize payment for a specific level of care, and for how many days. The reviewer typically applies the ASAM Criteria or a proprietary variant. If authorization is denied, the patient or provider can appeal. Understanding utilization review is central to navigating insurance coverage effectively.
Related: How to appeal an insurance denial
Medically supervised withdrawal management provided in an outpatient clinic, allowing the patient to sleep at home rather than staying in a facility overnight. Used when the medical risk of withdrawal is moderate but does not require 24-hour monitoring. Not appropriate for alcohol or benzodiazepine withdrawal that carries seizure risk without appropriate medical evaluation first.
The modern, clinical diagnosis for problematic alcohol use, replacing outdated and stigmatizing terms like "alcoholism" and "alcohol dependence." Defined by the DSM-5 as a pattern of alcohol use that causes clinically significant impairment or distress, with criteria including loss of control, withdrawal symptoms, tolerance, and continued use despite consequences. Severity is rated mild (2-3 criteria), moderate (4-5), or severe (6 or more).
The presence of both a substance use disorder and a mental health condition such as depression, anxiety, PTSD, bipolar disorder, or ADHD at the same time. Approximately half of people with a substance use disorder have at least one co-occurring mental health condition. Effective treatment addresses both simultaneously rather than treating one and waiting for the other.
The clinical diagnosis for problematic use of opioids, including prescription pain medication such as oxycodone or hydrocodone, heroin, or illicitly manufactured fentanyl. OUD has the strongest evidence base for medication treatment of any substance use disorder. Buprenorphine and methadone reduce overdose mortality by approximately 50 percent. Withholding medication from a patient with OUD is not a treatment decision, it is a harm.
The overarching medical diagnosis for the problematic use of any substance, including alcohol, opioids, stimulants, cannabis, benzodiazepines, and others. The DSM-5 categorizes SUD along a single severity spectrum (mild, moderate, or severe) rather than separating "abuse" from "dependence." SUD is a chronic, relapsing brain condition with genetic, environmental, and developmental contributors.
A heavily researched therapy framework focused on identifying and changing the immediate thought patterns and triggers that lead to substance use. CBT teaches patients to recognize high-risk situations, challenge distorted thinking, and develop concrete coping skills. It has strong randomized trial support for alcohol, opioid, cannabis, and stimulant use disorders. Standard outpatient CBT for SUD typically runs 12 to 16 sessions.
An evidence-based communication protocol that teaches family members and concerned significant others how to actively encourage a loved one into treatment without using confrontation, ultimatums, or detachment. CRAFT succeeds in getting treatment-refusing individuals into care at approximately three times the rate of Al-Anon facilitation and traditional intervention methods. It also reduces family members' own distress independent of whether the person enters treatment.
Related: CRAFT: evidence and how it works
Software applications that are FDA-cleared to actively treat a medical condition, not just track symptoms or provide information. Prescription digital therapeutics (PDTs) for substance use disorders typically require a prescriber's authorization and deliver structured CBT and contingency management curricula. reSET (for SUD) and reSET-O (for OUD) are the two FDA-authorized PDTs currently on the market for substance use.
Treatments and interventions that have been rigorously studied, tested, and proven to work by scientific research, typically through randomized controlled trials. In addiction care, evidence-based practices include CBT, motivational interviewing, CRAFT, contingency management, and medication-assisted treatment. The term is sometimes used loosely in marketing. A genuine EBP has peer-reviewed published data, not just clinical testimonials.
Practical, low-barrier strategies aimed at keeping people alive and reducing the physical, social, and legal risks of substance use, even when the individual is not ready or willing to stop using. Harm reduction approaches include naloxone distribution, fentanyl test strips, syringe exchange programs, safe consumption sites, and supervised medication tapering. Harm reduction and abstinence are not opposing philosophies. They operate on the same continuum of care.
Related: Harm reduction vs. abstinence: what people get wrong
A collaborative, person-centered conversation technique used by clinicians to help individuals explore and resolve their ambivalence about change and build their own internal motivation. MI does not push, confront, or lecture. Instead, the clinician listens for and reflects back the person's own reasons for change. It has strong evidence for increasing treatment engagement and reducing substance use across populations.
An FDA-approved medication for opioid use disorder, most recognized by the brand name Suboxone (buprenorphine combined with naloxone). Buprenorphine is a partial opioid agonist: it occupies opioid receptors strongly enough to stop withdrawal and cravings but has a ceiling effect that prevents a euphoric "high" at therapeutic doses. As of 2023, any clinician with a standard DEA registration can prescribe it, no additional certification required. Available as a daily dissolving film, daily tablet, monthly injectable (Sublocade), or six-month implant (Brixadi).
The standard medical practice of using FDA-approved medications to stabilize brain chemistry during recovery, usually combined with counseling and behavioral therapies. The term is increasingly replaced by MOUD (opioid-specific) and MAUD (alcohol-specific) in clinical settings, as "MAT" can imply that medication is merely an adjunct to "real" treatment. Medication is treatment. The research is unambiguous on this point.
The category of FDA-approved medications used to reduce alcohol cravings or block its rewarding effects. The three primary MAUD medications are naltrexone (reduces heavy drinking days and cravings), acamprosate (supports sustained abstinence after detox), and disulfiram (creates an aversive reaction if alcohol is consumed). Naltrexone is the most commonly prescribed. All three can be initiated in primary care without a specialist referral.
A full opioid agonist dispensed daily at federally regulated Opioid Treatment Programs (OTPs) to treat severe opioid use disorder. Methadone eliminates withdrawal symptoms and blocks cravings, and is one of the most effective treatments for OUD in terms of mortality reduction. In the US, federal regulations currently restrict methadone for OUD to licensed clinic settings, requiring daily in-person visits initially. It is not available for OUD through standard pharmacies or primary care in the way buprenorphine is.
The three FDA-approved medications proven to treat opioid use disorder: buprenorphine, methadone, and extended-release naltrexone (Vivitrol). MOUD reduces overdose mortality, decreases illicit opioid use, improves retention in treatment, and reduces criminal justice involvement. Despite the evidence, MOUD remains underutilized. Many residential programs still prohibit it under the false premise that taking a medication constitutes "not being in recovery."
Related: MOUD: full evidence overview
A non-addictive opioid antagonist that blocks the rewarding effects of both opioids and alcohol at the brain's opioid receptors. Available as a daily oral tablet (generic, low cost) or a monthly intramuscular injection (brand name Vivitrol). For alcohol use disorder, oral naltrexone reduces heavy drinking days significantly. For opioid use disorder, the monthly injectable is useful for patients who have already completed a 7 to 10 day opioid washout period and prefer a non-opioid option.